rsv-a

PC786 is a potent and selective non-nucleoside RSV L-protein polymerase inhibitor for inhalation therapy of RSV infections, with antiviral activity against RSV-A (IC50=0.09-0.71 nM) and RSV-B (IC 50=1.3-50.6 nM), and the ability to inhibit RSV RNA-dependent RNA polymerase in HEp-2 cells ( RdRp).

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

(R)-AZD 9639 is the R-isomer of AZD 9639, a novel respiratory syncytial virus (RSV) fusion inhibitor with antiviral activity.

YM-53403 is an antiviral activity that effectively inhibits the replication of RSV strains belonging to subgroup A and subgroup B. It can be used to treat respiratory syncytial virus infections.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

GS-443902 trisodium (GS-441524 triphosphate trisodium), the active triphosphate metabolite of Remdesivir (GS-5734), serves as a potent inhibitor of viral RNA-dependent RNA-polymerases (RdRp), displaying inhibitory concentrations (IC50) of 1.1 μM for RSV RdRp and 5 μM for HCV RdRp.

Umifenovir hydrochloride (Arbidol HCl) , an broad-spectrum antiviral chemical agent, can inhibit cell invade of enveloped viruses by blocking viral fusion with host cell membrane.

RD3-0028 is a potent and selective RSV replication inhibitor with an EC50 of 4.5 μM.

RSV604 R enantiomer is the R-enantiomer of RSV604, a replication inhibitor of respiratory syncytial virus (RSV).

Syncytial Virus Inhibitor-1 is a potent, orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion, with EC50 values of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively.

ALS-8112 (ALS 008112) is a selective and potent inhibitor of respiratory syncytial virus (RSV) polymerase with an IC50 value of 0.02 μM. ALS-8112 exhibits antiviral activity and inhibits the RNA polymerase activity of the RSV L-P protein complex through RNA chain termination. virus infections.

TMC353121 is a respiratory syncytial virus (RSV) fusion inhibitor with anti-RSV activity that inhibits the production of the inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines, KC, IP-10, MCP, and MIP1-α.

HRSV/HMPV-IN-1 (compound 3) is an inhibitor targeting HRSV/HMPV, exhibiting EC50 values of < 0.2 μM against human RSV-A and < 0.5 μM for human MPV A2 TN/94-49. This compound is utilized in the study of bronchiolitis and pneumonia.

CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.

MAY0132 is a potent and selective EPAC2 inhibitor with an IC50 of 0.4 μM. It significantly inhibits the replication of HMPV, AdV, and RSV, reduces cytokine/chemokine production induced by viral infections, and suppresses NF-κB activation. MAY0132 exhibits antiviral activity and can be used in respiratory virus infection research.

2-5A (5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine) pentasodium is a 5'-triphosphorylated (2',5') oligo-adenylate. Acting as an immune mediator, 2-5A pentasodium enhances the activity of RNase L. It degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its ribonuclease function. This compound is useful in research related to respiratory syncytial virus (RSV) and cancer.

2-5A is a 5'-triphosphorylated (2',5') oligoadenylate. It acts as an immune messenger capable of enhancing RNase L immunity. By binding to RNase L and activating its endoribonuclease activity, 2-5A degrades viral mRNA and inhibits protein synthesis. This compound is useful in research on respiratory syncytial virus (RSV) and cancer.

RV521 is a highly effective fusion inhibitor. It designed to treat RSV disease by the target of a surface protein that mediates RSV binding to cellular receptors.

RFI-641 is a dendrimer-like compound with anti-RSV properties and is effective in vitro and in vivo activity.

BMS-433771, a novel inhibitor of respiratory syncytial virus (RSV), binds the RSV F glycoprotein and inhibits membrane fusion.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with

trans-Trimethoxyresveratrol (MR-3), a natural methoxylated analog of resveratrol, inhibits breast Y cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

GS-441524tris-isobutyryl ester is a prodrug form of the antiviral nucleoside analog and remdesivir metabolite GS-441524 .1It reduces the cytopathic effect of respiratory syncytial virus (RSV) in infected HEp-2 cells with an EC50value of 0.26 μM. 1.Mackman, R.L., Hui, H.C., Perron, M., et al.Prodrugs of a 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the african green monkey model of RSVJ. Med. Chem.64(8)5001-5017(2021)